^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Yutuo (zimberelimab) (PD1 inhibitor) +
    etrumadenant (AB928) (Adenosine A2A receptor antagonist, Adenosine A2B receptor antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

    Excerpt:
    ...- Arm 1 and Arm 2 participants must have a sensitizing epidermal growth factor receptor (EGFR) mutation with disease progression or treatment intolerance after one or more approved TKIs....
    Trial ID:
    ARC-4
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2020
    Title:

    ARC-4: Efficacy and safety of AB928 plus carboplatin, pemetrexed and a PD-1 antibody in participants with metastatic non-small cell lung cancer (mNSCLC)

    Published date:
    09/14/2020
    Excerpt:
    ...11 pts have received AB928 in Ph 1: 75 mg (n=3), 150 mg (n=4); Ph1b: 150 mg + zimberelimab (n=4). ...Four pts (50%) achieved a partial response...2 TKI-experienced EGFRmut pts (erlotinib + osimertinib [n=1], osimertinib [n=1])...Combination treatment was associated with tumor shrinkage in all evaluable pts, including responses in those with PD after TKI or immunotherapy.
    Secondary therapy:
    carboplatin + pemetrexed